ADME-Tox in drug discovery: Integration of experimental and computational technologies

Drug Discovery Today

Volumn 8, Issue 18, 2003, Pages 852-861

  Yu, Hongshi ^a   Adedoyin, Adedayo ^b  

^a BIOGEN   (United States)

^b SANOFI   (France)

Author keywords

ADME Tox; ADME Tox assays; Biotechnology; Discovery support; Drug Discovery; Integration; Lead optimization; Pharmaceutical Science; Pharmacology; Techniques Methods; Virtual screening

Indexed keywords

BIOASSAY; COMPUTER MODEL; DRUG DEVELOPMENT; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; REVIEW; SCREENING TEST; STANDARDIZATION;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; PHARMACOLOGY, CLINICAL;

EID: 0042330313     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(03)02828-9     Document Type: Review

References (66)

1. Tollman, P. et al. (2001) A Revolution in R&D. How Genomics and Genetics are Transforming the Biopharmaceutical Industry, The Boston Consulting Group.
2. Rogers A.E., et al. Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development. Drug Disc. World. Summer. 67-:2002;71.
3. Dimasi J.A. Risks in new drug development: approval success rates for investigational drugs. Clin. Pharmacol. Ther. 69:2001;297-307.
4. Kennedy T. Managing the drug discovery/development interface. Drug Discov. Today. 2:1997;436-444.
5. Eddershaw P.J., et al. ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today. 5:2000;409-414.
6. Tarbit M.H., Breman J. High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds. Curr. Opin. Chem. Biol. 2:1998;411-416.
7. Smith D.A., van de Waterbeemd H. Pharmacokinetics and metabolism in early drug discovery. Curr. Opin. Chem. Biol. 3:1999;373-378.
8. Atterwill C.K., Wing M.G. In vitro preclinical lead optimization technologies (PLOTs) in pharmaceutical development. Toxicol. Lett. 127:2002;143-151.
9. Roberts S.A. Drug metabolism and pharmacokinetics in drug discovery. Curr. Opin. Drug Discov. Dev. 6:2003;66-80.
10. Lin J., et al. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem. 3:2003;1125-1154.
11. Andrews J., et al. Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 32:2002;937-947.
12. Adachi Y., et al. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 18:2001;1660-1668.
13. Thompson T.N. Optimization of metabolic stability as a goal of modern drug design. Med. Res. Rev. 21:2001;412-449.
14. Johnson D.L., et al. Single point screening for high throughput methods to predict drug-drug interaction potential. Drug Metab. Rev. 32:(suppl. 2):2000;185.
15. i in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab. Dispos. 27:1999;756-762.
16. Ackermann B.L., et al. Recent advances in use of LC/MS/MS for quantitative high-throughput bioanalytical support of drug discovery. Curr. Top. Med. Chem. 2:2003;53-66.
17. Xu R., et al. Application of parallel liquid chromatography/mss spectrometry for high throughput microsomal stability screening of compounds libraries. J. Am. Soc. Mass Spectrom. 13:2002;155-165.
18. Crespi C.L., et al. Microtiter plate assays for inhibition of human, drug metabolizing cytochromes P450. Anal. Biochem. 248:1997;188-190.
19. Crespi C.L., et al. High throughput screening for inhibition of cytochrome P450 metabolism. Med. Chem. Res. 8:1998;457-471.
20. Bevan C.D. A high-throughput screening method for the determination of aqueous drug solubility using laser nephelometry in microtiter plates. Anal. Chem. 72:2000;1781-1787.
21. Kerns E.H. High throughput physicochemical profiling for drug discovery. J. Pharm. Sci. 90:2001;1838-1858.
22. Kerns E.H., Di L. Pharmaceutical profiling in drug discovery. Drug Discov. Today. 8:2003;316-323.
23. Ekins S., et al. Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods. 44:2000;251-272.
24. Beresford A.P., et al. The emerging importance of predictive ADME simulation in drug discovery. Drug Discov. Today. 7:2002;109-116.
25. Butina D., et al. Predicting ADME properties in silico: methods and models. Drug Discov. Today. 7:(Suppl):2002;S83-S88.
26. Boobis A., et al. In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organized by COST B15. Eur. J. Pharm. Sci. 17:2002;183-193.
27. Van de Waterbeemd H., Gifford E. ADMET in silico modeling: towards prediction paradise? Nat. Rev. Drug Discov. 2:2003;192-204.
28. Ekins S., et al. Towards a new age of virtual ADME/TOX and multidimensional drug discovery. Mol. Divers. 5:2002;255-275.
29. Clark D.E., Pickett S.D. Computational methods for the prediction of 'drug-likeness'. Drug Discov. Today. 5:2000;49-58.
30. Segall M.D., Beresford A.P. Virtual ADME-Tox: The promise of technology in pre-clinical development. Sansom C. Enabling Technologies: Delivering the future for Pharmaceutical R&D. 2002;93-119 PJB Publications.
31. Wilson A.G.E., et al. Role of predictive metabolism and toxicity modeling in drug discovery - A summary of some recent advancements. Curr. Opin. Drug Discov. Dev. 6:2003;123-128.
32. Liu R., So S.S. Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 1. Aqueous solubility. J. Chem. Inf. Comput. Sci. 41:2001;1633-1639.
33. Liu R., et al. Development of quantitative structure-property relationship models for early ADME evaluation in drug discovery. 2. Blood-brain barrier. J. Chem. Inf. Comput. Sci. 41:2001;1623-1632.
34. Clark D.E. Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 1. Prediction of intestinal absorption. J. Pharm. Sci. 88:1999;807-814.
35. Zhao Y.H., et al. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with Abraham descriptors. J. Pharm. Sci. 90:2001;749-784.
36. Jones J.P., et al. Computational models for cytochrome P450: a predictive electronic model for aromatic oxidation and hydrogen atom abstraction. Drug Metab. Dispos. 30:2002;7-12.
37. Segall M.D., et al. Ab initio molecular modeling in the study of drug metabolism. Eur. J. Drug Metab. Pharmacokinet. 22:1997;283-288.
38. Jones J.P., et al. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab. Dispos. 24:1996;1-6.
39. Jones J.P., Korzekwa K.R. Predicting the rates and regioselectivity of reactions mediated by the P450 superfamily. Methods in Enzymology. 1996;326-335 Academic Press.
40. Cheng A., et al. Computation of the physio-chemical properties and data mining of large molecular collections. J. Comput. Chem. 23:2002;172-183.
41. Teague S.J., et al. The design of leadlike combinatiorial libraries. Angew. Chem. Int. Ed. Engl. 38:1999;3743-3748.
42. Martin E.J., Critchlow R. Beyond mere diversity: tailoring combinatorial libraries for drug discovery. J. Comb. Chem. 1:1999;32-45.
43. Van de Waterbeemd H. High-throughput and techniques in drug metabolism and pharmacokinetics. Curr. Opin. Drug Discov. Dev. 5:2002;33-43.
44. Manly C.J., et al. The impact of informatics and computational chemistry on synthesis and screening. Drug Discov. Today. 6:2001;1101-1110.
45. Li A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today. 6:2001;357-366.
46. Ekins S., Rose J. In silico ADME/Tox: the state of the art. J. Mol. Graph. Model. 20:2002;305-309.
47. Clark D.E., Grootenhuis P.D.J. Progress in computational methods for the prediction of ADME-Tox. Curr. Opin. Drug Discov. Dev. 5:2002;382-390.
48. Langowski J., Long A. Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Deliv. Rev. 54:2002;407-415.
49. Gombar V.K., et al. Role of ADME characteristics in drug discovery and their in silico evaluation: In silico screening of chemicals for their metabolic stability. Curr. Top. Med. Chem. 3:2003;1205-1225.
50. Bohets H., et al. Strategies for absorption screening in drug discovery and development. Curr. Top. Med. Chem. 1:2001;367-383.
51. Hidalgo I.J. Assessing the absorption of new pharmaceuticals. Curr. Top. Med. Chem. 1:2001;385-401.
52. Balimane P.V., et al. Current methodologies used for evaluation of intestinal permeability and absorption. J. Pharmacol. Toxicol. Methods. 44:2000;301-312.
53. Parrott N., Lavé T. Prediction of intestinal absorption: comparative assessment of GASTRPLUS™ and IDEA™ Eur. J. Pharm. Sci. 17:2002;51-61.
54. Egan W.J., Lauri G. Prediction of intestinal permeability. Adv. Drug Deliv. Rev. 54:2002;273-289.
55. Klopman G., et al. ADME evaluation 2. A computer model for the prediction of intestinal absorption in humans. Eur. J. Pharm. Sci. 17:2002;253-263.
56. Masimirembwa C.M., et al. Metabolic stability for drug discovery and development. Clin. Pharmacokin. 42:2003;515-528.
57. Ekins S., Wrighton S. Application of in silico approaches to predicting drug-drug interactions. J. Pharmacol. Toxicol. Methods. 45:2001;65-69.
58. Gumbleton M., Audus K.L. Progress and limitations in the use of in vitro cell cultures to serve a permeability screen for the blood-brain barrier. J. Pharm. Sci. 90:2001;1681-1698.
59. Lohmann C., et al. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J. Drug Target. 10:2002;263-276.
60. Di L., et al. High throughput artificial membrane permeability assay for blood-brain barrier. Eur. J. Med. Chem. 38:2003;223-232.
61. Lobell M., et al. Recent advances in the prediction of blood-brain partitioning from molecular structure. J. Pharm. Sci. 92:2003;360-370.
62. Polli J., et al. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299:2001;620-628.
63. Kratochwil N.A., et al. Predicting plasma protein binding of drugs: a new approach. Biochem. Pharmacol. 64:2002;1355-1374.
64. Wolfgang G.H.I., Johnson D.E. Web resources for drug toxicity. Toxicology. 173:2002;67-74.
65. Blaauboer B.J. The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modeling a tool in hazard and risk assessment. A commentary. Toxicol. Lett. 138:2002;161-171.
66. Reifferscheid G., Heil J. Validation of the SOS/umu test using test results of 486 chemicals and comparison with the AMES test and carcinogenicity data. Mutat. Res. 369:1996;129-145.